Company Summary

LeukoVet is developing a peptide-based cancer therapeutic for treatment of canine lymphoma, leukemia, and other immunological diseases. Leukovet’s technology targets activated white blood cells and holds the potential to vastly improve the lives of millions of companion animals while avoiding the toxicity and side-effects associated with conventional chemotherapies. Leukovet believes a cure for blood cancers is in reach and is focused on bringing a new therapeutic option to companion animals in need.

Year Founded: 2019

Key Executives:
• Scott Kachlany, Ph.D., Scientific Founder and Director
• Sonia Gulati, Ph.D., Interim CEO

Location:  New York, NY

Company Status:  Private

Year Invested:  2019

Investment Status:  Current

Board Member:
Nikos Iatropoulos
Sonia Gulati, Ph.D.